# OnCo record gvhd-ruxolitinib-steroid-refractory (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/gvhd-ruxolitinib-steroid-refractory/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "gvhd-ruxolitinib-steroid-refractory" ;
  schema:name "When steroids fail: ruxolitinib for steroid-refractory GvHD"@en ;
  schema:alternateName "REACH2"@en, "REACH3"@en, "steroid-refractory GvHD"@en, "glucocorticoid-refractory GVHD"@en, "JAK inhibitor for GvHD"@en ;
  schema:description "First treatment for graft-versus-host disease is steroids, and in about half of people with chronic disease they do not work or cannot be reduced. Ruxolitinib is the only drug that has beaten the alternatives in a randomised trial here, and it has done so twice. About half of people respond; the common problems are low platelets and low haemoglobin."@en ;
  schema:url <https://onco.cc/technologies/gvhd-ruxolitinib-steroid-refractory/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Ruxolitinib> ;
  schema:citation <https://doi.org/10.1056/NEJMoa1917635>, <https://doi.org/10.1056/NEJMoa2033122>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1c82580-87ae-11e0-bc84-0002a5d5c51b>, <https://doi.org/10.1016/j.bbmt.2014.12.001> ;
  onco:status "approved" ;
  onco:tag "rejuvenation", "survivorship", "transplant", "evidence:strong", "gvhd", "treatment" ;
  onco:related <https://onco.cc/technologies/gvhd-chronic-overview/>, <https://onco.cc/technologies/gvhd-belumosudil-axatilimab-ibrutinib/>, <https://onco.cc/technologies/gvhd-photopheresis/>, <https://onco.cc/technologies/gvhd-nih-consensus-criteria/>, <https://onco.cc/technologies/gvhd-lung-bronchiolitis-obliterans/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/allogeneic-hsct/> ;
  onco:drugs <https://onco.cc/drugs/ruxolitinib/> ;
  onco:terms <https://onco.cc/terms/gvhd/>, <https://onco.cc/terms/cytopenias/>, <https://onco.cc/terms/quality-of-life/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> .